Timothy A Chan

List of Publications by Year in Descending Order

163 papers	29,990 citations	64 h-index	173 g-index
183 ext. papers	39,312 ext. citations	16.4 avg, IF	6.98 L-index

#	Paper	IF	Citations
163	Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients.. *Aging Cell*, **2022**, e13544	9.9	2
162	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade.. *Npj Precision Oncology*, **2022**, 6, 23	9.8	1
161	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.. *Neoplasia*, **2022**, 28, 100790	6.4	0
160	Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade.. *JAMA Network Open*, **2022**, 5, e220448	10.4	1
159	H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2114324119	11.5	2
158	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. *Clinical Cancer Research*, **2021**, 27, 1516-1525	12.9	2
157	The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. *Blood*, **2021**,	2.2	2
156	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. *American Journal of Cancer Research*, **2021**, 11, 3628-3644	4.4	2
155	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. *Nature Communications*, **2021**, 12, 6821	17.4	2
154	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. *Molecular Cancer Research*, **2021**,	6.6	2
153	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. *Nature Biotechnology*, **2021**,	44.5	10
152	Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. *Nature Cancer*, **2021**, 1, 1188-1203	15.4	43
151	Immunotherapy biomarkers: the long and winding road. *Nature Reviews Clinical Oncology*, **2021**, 18, 323-324	39.4	2
150	Qa-1 Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. *Molecular Cancer Research*, **2021**, 19, 1076-1084	6.6	3
149	Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity. *JAMA Network Open*, **2021**, 4, e217746	10.4	13
148	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. *Molecular Cancer Research*, **2021**, 19, 1510-1521	6.6	2
147	Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). *Pharmaceuticals*, **2021**, 14,	5.2	11

146	Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. *JAMA Oncology*, **2021**, 7, 739-743	13.4	40
145	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. *Cancer Cell*, **2021**, 39, 662-677.e6	24.3	28
144	Resource-efficient pooled sequencing expands translational impact in solid tumors. *Kidney Cancer Journal: Official Journal of the Kidney Cancer Association*, **2021**, 19, 18-23	0.1	0
143	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 5595-5606	12.9	3
142	Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19. *Signal Transduction and Targeted Therapy* , **2021**, 6, 292	21	3
141	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. *Journal of the National Cancer Institute*, **2021**, 113, 266-273	9.7	15
140	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. *European Urology Focus*, **2021**, 7, 381-389	5.1	7
139	The association between tumor mutational burden and prognosis is dependent on treatment context. *Nature Genetics*, **2021**, 53, 11-15	36.3	38
138	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. *Journal of the National Cancer Institute*, **2021**, 113, 742-751	9.7	39
137	Precision regenerative medicine. *Stem Cell Research and Therapy*, **2021**, 12, 39	8.3	2
136	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. *Nature Communications*, **2021**, 12, 729	17.4	44
135	Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-Reply. *JAMA Oncology*, **2021**, 7, 1245-1246	13.4	
134	Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. *Science Translational Medicine*, **2021**, 13, eabg4328	17.5	1
133	My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. *Genome Biology*, **2021**, 22, 53	18.3	7
132	A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19. *ChemRxiv*, **2020**,	4.4	5
131	Diverse Neoantigens and the Development of Cancer Therapies. *Seminars in Radiation Oncology*, **2020**, 30, 113-128	5.5	7
130	Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. *Science Advances*, **2020**, 6, eaaz3221	14.3	32
129	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. *Cancers*, **2020**, 12,	6.6	30

#	Reference	IF	Citations
110	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 **2020**, 18, e3000970		
109	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 **2020**, 18, e3000970		
108	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 **2020**, 18, e3000970		
107	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 **2020**, 18, e3000970		
106	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 **2020**, 18, e3000970		
105	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19 **2020**, 18, e3000970		
104	RIG-I activation is critical for responsiveness to checkpoint blockade. *Science Immunology*, **2019**, 4,	28	47
103	Lung Cancer Evolution: What's Immunity Got to Do with It?. *Cancer Cell*, **2019**, 35, 711-713	24.3	5
102	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. *Nature Medicine*, **2019**, 25, 767-775	50.5	149
101	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. *Science*, **2019**, 364, 485-491	33.3	228
100	CD8 T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature*, **2019**, 569, 270-274	50.4	632
99	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. *Journal of Neuro-Oncology*, **2019**, 142, 523-528	4.8	3
98	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nature Reviews Cancer*, **2019**, 19, 133-150	31.3	996
97	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. *Nature Communications*, **2019**, 10, 943	17.4	79
96	CD97 is a critical regulator of acute myeloid leukemia stem cell function. *Journal of Experimental Medicine*, **2019**, 216, 2362-2377	16.6	11
95	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. *Oral Oncology*, **2019**, 96, 140-147	4.4	21
94	The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. *Genome Medicine*, **2019**, 11, 43	14.4	13
93	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. *Oncotarget*, **2019**, 10, 3835-3839	3.3	5

#	Reference		
92	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. *Clinical Cancer Research*, **2019**, 25, 5537-5547	12.9	48
91	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. *Journal of Clinical Investigation*, **2019**, 129, 4276-4289	15.9	64
90	RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade. *Blood*, **2019**, 134, 624-624	2.2	1
89	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. *Nature Medicine*, **2019**, 25, 1715-1720	50.5	89
88	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. *Neuro-Oncology*, **2019**, 21, 189-200	1	33
87	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. *Cancer Discovery*, **2019**, 9, 510-525	24.4	88
86	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nature Genetics*, **2019**, 51, 202-206	36.3	1435
85	Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. *Clinical Cancer Research*, **2019**, 25, 1226-1232	12.9	16
84	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. *Journal of the National Cancer Institute*, **2018**, 110, 1386-1392	9.7	78
83	ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. *Cancer Immunology Research*, **2018**, 6, 151-162	12.5	25
82	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. *Clinical Cancer Research*, **2018**, 24, 963-971	12.9	34
81	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. *BMC Cancer*, **2018**, 18, 225	4.8	17
80	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. *Nature Communications*, **2018**, 9, 1057	17.4	39
79	Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 833-844	4	1
78	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. *Trends in Immunology*, **2018**, 39, 536-548	14.4	91
77	Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. *Cancer Cell*, **2018**, 34, 256-270.e5	24.3	103
76	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. *Nature Genetics*, **2018**, 50, 62-72	36.3	86
75	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. *Science*, **2018**, 359, 582-587	33.3	500

#			
74	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. *Journal of Clinical Oncology*, **2018**, 36, 1702-1709	2.2	27
73	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. *Lancet Oncology, The*, **2018**, 19, 1688-1698	21.7	70
72	ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. *Nature Communications*, **2018**, 9, 4158	17.4	80
71	The hallmarks of successful anticancer immunotherapy. *Science Translational Medicine*, **2018**, 10,	17.5	260
70	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. *Clinical Cancer Research*, **2017**, 23, 3168-3180	12.9	51
69	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of and as Novel Thyroid Cancer Genes Associated with Tumor Virulence. *Clinical Cancer Research*, **2017**, 23, 5970-5980	12.9	64
68	Dissecting microsatellite instability in colorectal cancer: one size does not fit all. *Genome Medicine*, **2017**, 9, 45	14.4	3
67	Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5x6Gy) conformal radiotherapy. *Radiotherapy and Oncology*, **2017**, 123, 203-208	5.3	12
66	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. *Clinical Cancer Research*, **2017**, 23, 4429-4440	12.9	108
65	Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. *Neoplasia*, **2017**, 19, 75-83	6.4	23
64	Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. *Clinical Cancer Research*, **2017**, 23, 3109-3119	12.9	13
63	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. *Nature Communications*, **2017**, 8, 1197	17.4	46
62	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. *Cell*, **2017**, 171, 934-949.e16	36.2	831
61	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment **2017**, 5, 76		78
60	NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. *Cell*, **2017**, 170, 1096-1108.e13	36.2	151
59	An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. *Cell Reports*, **2017**, 20, 1623-1640	10.6	59
58	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. *Nature*, **2017**, 551, 512-516	50.4	533
57	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. *Nature*, **2017**, 551, 517-520	50.4	336

56	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 797-804	4	27
55	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. *JAMA Oncology*, **2017**, 3, 244-255	13.4	141
54	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM. *Oncotarget*, **2017**, 8, 10312-10323	3.3	23
53	PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. *Oncotarget*, **2017**, 8, 15827-15837	3.3	13
52	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biology*, **2016**, 17, 231	18.3	391
51	FAT1 mutations cause a glomerulotubular nephropathy. *Nature Communications*, **2016**, 7, 10822	17.4	69
50	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. *Molecular and Cellular Oncology*, **2016**, 3, e1048929	1.2	24
49	Regularized quantile regression under heterogeneous sparsity with application to quantitative genetic traits. *Computational Statistics and Data Analysis*, **2016**, 95, 222-239	1.6	15
48	Immunotherapy and Oncogenic Pathways: The PTEN Connection. *Cancer Discovery*, **2016**, 6, 128-9	24.4	16
47	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science*, **2016**, 351, 1463-9	33.3	1758
46	Integrated genomic characterization of IDH1-mutant glioma malignant progression. *Nature Genetics*, **2016**, 48, 59-66	36.3	185
45	Cancer Neoantigens and Applications for Immunotherapy. *Clinical Cancer Research*, **2016**, 22, 807-12	12.9	146
44	CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function. *Blood*, **2016**, 128, 1077-1077	2.2	2
43	The head and neck cancer immune landscape and its immunotherapeutic implications. *JCI Insight*, **2016**, 1, e89829	9.9	356
42	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. *Oncotarget*, **2016**, 7, 3403-15	3.3	229
41	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. *Oncotarget*, **2016**, 7, 10051-63	3.3	169
40	Corticosteroids compromise survival in glioblastoma. *Brain*, **2016**, 139, 1458-71	11.2	205
39	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 4623-33	12.9	114

38	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. *Clinical Cancer Research*, **2016**, 22, 4786-4796	12.9	69
37	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. *Cancer Cell*, **2016**, 29, 737-750	24.3	31
36	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. *Cancer Discovery*, **2016**, 6, 703-13	24.4	64
35	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. *Nature Genetics*, **2016**, 48, 1327-1329	36.3	84
34	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. *Cancer Research*, **2016**, 76, 6495-6506	10.1	68
33	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
32	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*, **2015**, 348, 124-8	33.3	5003
31	Genetics and immunology: reinvigorated. *OncoImmunology*, **2015**, 4, e1029705	7.2	7
30	Genomic landscape of adenoid cystic carcinoma of the breast. *Journal of Pathology*, **2015**, 237, 179-89	9.4	101
29	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. *Journal of Neuro-Oncology*, **2015**, 125, 149-56	4.8	165
28	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. *Cell*, **2015**, 162, 974-86	56.2	872
27	ATPS-44INHIBITION OF POLO-LIKE KINASE 1 SENSITIZESISOCITRATE DEHYDROGENASE 1MUTANT ASTROCYTES TO TEMOZOLOMIDE TREATMENT. *Neuro-Oncology*, **2015**, 17, v27.5-v28	1	78
26	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. *PLoS ONE*, **2015**, 10, e0135750	3.7	32
25	Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 368-75	4	268
24	Immunogenic peptide discovery in cancer genomes. *Current Opinion in Genetics and Development*, **2015**, 30, 7-16	4.9	53
23	Transcriptional diversity of long-term glioblastoma survivors. *Neuro-Oncology*, **2014**, 16, 1186-95	1	55
22	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. *Nature Genetics*, **2014**, 46, 588-94	36.3	124
21	Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. *Clinical Cancer Research*, **2014**, 20, 5023-31	12.9	70

20	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. *Genes and Diseases*, **2014**, 1, 75-86	6.6	65
19	Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 518-25	4	23
18	A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 130-6	4	173
17	Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 322-9	4	74
16	Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. *Cell*, **2014**, 156, 603-616	56.2	184
15	Remodeling of the methylation landscape in breast cancer metastasis. *PLoS ONE*, **2014**, 9, e103896	3.7	25
14	Survival of patients treated with radiation therapy for anaplastic astrocytoma. *Radiology and Oncology*, **2014**, 48, 381-6	3.8	5
13	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. *Cancer Biology and Therapy*, **2014**, 15, 623-32	4.6	25
12	Genetic basis for clinical response to CTLA-4 blockade in melanoma. *New England Journal of Medicine*, **2014**, 371, 2189-2199	59.2	2802
11	Cancer: Antitumour immunity gets a boost. *Nature*, **2014**, 515, 496-8	50.4	77
10	Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. *Oncotarget*, **2014**, 5, 6976-82	3.3	17
9	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science*, **2013**, 340, 626-30	33.3	855
8	The mutational landscape of adenoid cystic carcinoma. *Nature Genetics*, **2013**, 45, 791-8	36.3	311
7	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. *Nature Medicine*, **2013**, 19, 901-908	50.5	279
6	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. *Oncotarget*, **2013**, 4, 1737-47	3.3	119
5	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. *Oncotarget*, **2013**, 4, 1729-36	3.3	171
4	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. *Clinical Cancer Research*, **2012**, 18, 2490-501	12.9	108
3	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature*, **2012**, 483, 479-83	30.4	1373

2   IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature*, **2012**, 483, 474-8   50.4   1393

1   Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. *Oncotarget*, **2012**, 3, 1194-203   3.3   200